Structure (C8872d2a F3a8 4615 A89b 4a829a503eb0 01)
Gabarone Tablet
Product Images NDC 74157-013
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabarone (NDC 74157-013). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Ina Pharmaceutics Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (C8872d2a F3a8 4615 A89b 4a829a503eb0 02)
This text appears to be a chart showing the Mean Pain Score over different weeks in a study comparing a placebo with Gabapentin at 3600 mg/day dosage. The study includes a 4-week Dose Titration Period followed by a 4-week Fixed Dose Period. The chart likely shows the pain scores at Baseline, Week 1 to Week 8 for each treatment group (Placebo and Gabapentin).*
Figure 2 (C8872d2a F3a8 4615 A89b 4a829a503eb0 03)
This document provides a comparison of mean pain scores during a clinical trial involving a 3-week dose titration period followed by a 4-week fixed-dose period with different treatments such as placebo, Gabapentin at 1800 mg/day, and Gabapentin at 2400 mg/day. The chart displays the pain scores over 7 weeks, allowing for the evaluation of the effects of the treatments on pain management.*
Figure 3 (C8872d2a F3a8 4615 A89b 4a829a503eb0 04)
This text presents data regarding the proportion of responders in controlled postherpetic neuralgia (PHN) studies based on pain score reduction. The figures indicate the percentage of patients with more than 50% reduction in pain score at the study endpoint. The data is detailed for different dosages of gabapentin (GBP) compared to a placebo (PBO) group. Study 1 appears to involve different dosages of GBP (3600 mg, 1800 mg, and 2400 mg) in comparison to a placebo group. The statistical significance levels are also provided (<0.01 and <0.001).*
Figure 4 (C8872d2a F3a8 4615 A89b 4a829a503eb0 05)
The text is not readable.*
100mg-90s (C8872d2a F3a8 4615 A89b 4a829a503eb0 06)
400mg-90s (C8872d2a F3a8 4615 A89b 4a829a503eb0 07)
This is a description of Gabapentin tablets, each containing 400 mg of Gabapentin, USP. The usual dosage and storage information is provided on the packaging, which is child-resistant and should be stored at 25°C. The medication should be kept tightly closed and out of reach of children. The tablets are named "Gabarone" and are intended for prescription use only. The manufacturer is INA Pharmaceutics Inc. located in Fairmont, WV. Pharmacies are advised to dispense a Medication Guide to each patient along with the tablets.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
